AU Patent

AU2017311585A1 — Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor

Assigned to Genentech Inc · Expires 2019-02-28 · 7y expired

What this patent protects

A combination therapy comprising a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor is provided for the treatment of colorectal cancer and metastatic colorectal cancer.

USPTO Abstract

A combination therapy comprising a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor is provided for the treatment of colorectal cancer and metastatic colorectal cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017311585A1
Jurisdiction
AU
Classification
—
Expires
2019-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.